Top

Published in:

01-09-2011 | Original Article

Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer

Authors: M. Tahara, H. Minami, Y. Hasegawa, K. Tomita, A. Watanabe, K. Nibu, M. Fujii, Y. Onozawa, Y. Kurono, D. Sagae, T. Seriu, M. Tsukuda

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2011

Abstract

Purpose

To evaluate the efficacy and safety of weekly paclitaxel in patients with recurrent or metastatic head and neck cancer (HNC) by combined analysis of early and late phase II trials.

Methods

Eligibility criteria included histologically proven HNC with recurrent or metastatic disease, measurable disease, PS 0-2, and one or no prior chemotherapy regimens. Treatment consisted of a 1-h infusion of paclitaxel at a dose of 100 mg/m² weekly for 6 weeks of a 7-week cycle. A total of 74 patients were enrolled: 37 between February and November 2004 in an early phase II trial and 37 between October 2005 and July 2006 in a late phase II trial.

Results

The median number of treatment cycles was two, and median dose intensity was 84.2 mg/m²/week. The most common grade 3–4 adverse events were leukopenia (37.5%), neutropenia (30.6%), anemia (12.5%), constipation (8.3%), peripheral neuropathy (5.6%), anorexia (5.6%), and pneumonitis (5.6%). Overall response rate was 29.0% according to RECIST. The median duration of response, median time to progression, and median survival time were 7.4, 3.4, and 14.3 months, respectively.

Conclusions

This study demonstrates that weekly paclitaxel has promising activity with acceptable toxicity in the treatment of recurrent or metastatic HNC.

The Liverpool Head and Neck Oncology Group (1990) A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61:311–315

Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, Iconomou G, Kalofonos HP (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64:26–31PubMedCrossRef

Brotherton T (2001) Multicenter phase II trial of paclitaxel (taxol) (T): weekly one-hour infusion in previously treated advanced head/neck cancer (AHNC). ASCO, p 231a (abstract 921)

Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M et al (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521–526PubMed

Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245–1251PubMed

Forastiere AA, Shank D, Neuberg D, SGt Taylor, DeConti RC, Adams G (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82:2270–2274PubMedCrossRef

Gebbia V, Valenza R, Testa A, Borsellino N, Cannata G, Restivo S, Speciale R, Ingria F, Spadafora G, Gebbia N (1994) Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck. ORL J Otorhinolaryngol Relat Spec 56:279–282PubMedCrossRef

Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17:3038–3047PubMed

Grau JJ, Caballero M, Verger E, Monzo M, Blanch JL (2009) Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 129:1294–1299PubMedCrossRef

10.

Herrero FR, Hitt R, Kawecki A, Rottey S, Peyrade F, Vynnychenko I, Curran D, Kisker O, Gross A, Vermorken JB (2008) Cetuximab plus platinum-based therapy first line in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A quality of life (QOL) analysis of the EXTREME trial. 33rd ESMO Congress. Annals of Oncology, Stockholm, Sweden, p 219 (abstract 693PD)

11.

Inuyama Y, Kataura A, Togawa K, Saijo S, Satake B, Takeoda S, Konno A, Ebihara S, Sasaki Y, Kida A, Kanzaki J, Ichikawa G, Kono N, Moriyama H, Kamata S, Miyake H, Sakai M, Horiuchi M, Kubota A, Tsukuda M, Matsuura H, Baba S, Saito H, Matsunaga T, Taguchi T et al (1999) Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Gan To Kagaku Ryoho 26:107–116PubMed

12.

Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (1998) Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group). Gan To Kagaku Ryoho 25:1151–1158PubMed

13.

Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (2001) Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28:1381–1390PubMed

14.

Iop A, Cartei G, Isaia A (1998) Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil. Ann Oncol 9:225–227PubMedCrossRef

15.

Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257–263PubMed

16.

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

17.

Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V (2010) Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 28:8–14PubMedCrossRef

18.

Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy B, Rowland KM, Smith DA, Berg A, Stella PJ, Loprinzi CL (2009) The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: a phase III double-blind, placebo controlled study-N05C3. 2009 ASCO Annual Meeting. J Clin Oncol (Orlando), p 491s (abstract 9532)

19.

Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, Chew L, Lim SH, Wee J, Lee KM, Foo KF, Ang P, Ang PT (2003) Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21:1767–1774PubMedCrossRef

20.

Nokihara H, Tamura T, Matsumoto Y (2002) Weekly paclitaxel in solid tumor, a phase I trial. Jpn J Lung Cancer. In: 43rd Annual meeting, abstract 395

21.

Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, Forman S, Margolin K, Morgan R, Shibata S, Somlo G (2004) Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 10:461–467PubMedCrossRef

22.

Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827–841PubMedCrossRef

23.

Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118PubMedCrossRef

24.

Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093–4100PubMed

25.

Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE (2008) Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 19:1787–1794PubMedCrossRef

26.

Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667PubMedCrossRef

27.

Smith RE, Thornton DE, Allen J (1995) A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 22:41–46PubMed

28.

Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671PubMedCrossRef

29.

Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J (2008) Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112:2710–2719PubMedCrossRef

30.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127PubMedCrossRef

31.

Vogl SE, Schoenfeld DA, Kaplan BH, Lerner HJ, Engstrom PF, Horton J (1985) A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56:432–442PubMedCrossRef

32.

Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Head and neck cancer. N Engl J Med 328:184–194PubMedCrossRef

33.

Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999) Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Semin Radiat Oncol 9:77–84PubMed

34.

Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327PubMedCrossRef

35.

Williams SD, Velez-Garcia E, Essessee I, Ratkin G, Birch R, Einhorn LH (1986) Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 57:18–23PubMedCrossRef

36.

Zenda S, Onozawa Y, Boku N, Iida Y, Ebihara M, Onitsuka T (2007) Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol 37:477–481PubMedCrossRef

Title: Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer
Authors: M. Tahara
H. Minami
Y. Hasegawa
K. Tomita
A. Watanabe
K. Nibu
M. Fujii
Y. Onozawa
Y. Kurono
D. Sagae
T. Seriu
M. Tsukuda
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1550-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin

Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines

Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer

Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer